Freidel M - Search Results

1

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.

Freidel M, Tiel-Wilck K, Schreiber H, Prechtl A, Essner U, Lang M. Freidel M, et al. Acta Neurol Scand. 2015 Jan;131(1):9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11. Acta Neurol Scand. 2015. PMID: 25208898

2

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.

Kolb-Mäurer A, Sunderkötter C, Kukowski B, Meuth SG; members of an expert meeting. Kolb-Mäurer A, et al. BMC Neurol. 2019 Jun 15;19(1):130. doi: 10.1186/s12883-019-1354-y. BMC Neurol. 2019. PMID: 31202258 Free PMC article.

3

[Oxcarbazepine in the treatment of epilepsy].

Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Freidel M, et al. Fortschr Neurol Psychiatr. 2007 Feb;75(2):100-6. doi: 10.1055/s-2006-932218. Epub 2007 Jan 2. Fortschr Neurol Psychiatr. 2007. PMID: 17200915 German.

4

Symptomatology of MS: results from the German MS Registry.

Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P. Stuke K, et al. Among authors: freidel m. J Neurol. 2009 Nov;256(11):1932-5. doi: 10.1007/s00415-009-5257-5. Epub 2009 Jul 23. J Neurol. 2009. PMID: 19629565

5

Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study.

Freidel M, Ortler S, Fuchs A, Seibert S, Schuh K. Freidel M, et al. J Neurosci Nurs. 2015 Feb;47(1):E31-9. doi: 10.1097/JNN.0000000000000100. J Neurosci Nurs. 2015. PMID: 25285595 Free PMC article.

6

Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

Flachenecker P, Stuke K, Elias W, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Zettl UK, Rieckmann P. Flachenecker P, et al. Among authors: freidel m. Dtsch Arztebl Int. 2008 Feb;105(7):113-9. doi: 10.3238/arztebl.2008.0113. Epub 2008 Feb 15. Dtsch Arztebl Int. 2008. PMID: 19633761 Free PMC article.

7

Costs and quality of life of multiple sclerosis in Germany.

Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, König N, Limmroth V, Straube E. Kobelt G, et al. Among authors: freidel m. Eur J Health Econ. 2006 Sep;7 Suppl 2:S34-44. doi: 10.1007/s10198-006-0384-8. Eur J Health Econ. 2006. PMID: 17310337

8

The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein.

Freidel MR, Vakhariya PA, Sardarni SK, Armen RS. Freidel MR, et al. Viruses. 2024 Apr 20;16(4):640. doi: 10.3390/v16040640. Viruses. 2024. PMID: 38675980 Free PMC article.

9

Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.

Freidel MR, Armen RS. Freidel MR, et al. J Chem Inf Model. 2021 Dec 27;61(12):5906-5922. doi: 10.1021/acs.jcim.1c01061. Epub 2021 Dec 13. J Chem Inf Model. 2021. PMID: 34898207 Free PMC article.

10

Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.

Freidel MR, Armen RS. Freidel MR, et al. PLoS One. 2021 Feb 17;16(2):e0246181. doi: 10.1371/journal.pone.0246181. eCollection 2021. PLoS One. 2021. PMID: 33596235 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page